Harvard Apparatus RT Files 8-K on Material Agreement, Financial Obligation

TL;DR

**Harvard Apparatus RT just took on a new material agreement and financial obligation, watch for details.**

AI Summary

Harvard Apparatus Regenerative Technology, Inc. (formerly Biostage, Inc.) filed an 8-K on February 6, 2024, reporting an event that occurred on February 1, 2024. This filing indicates the company entered into a material definitive agreement and created a direct financial obligation or an off-balance sheet arrangement. This matters to investors because such agreements and obligations can significantly impact the company's financial health, future operations, and ultimately, the stock's value, potentially signaling new strategic directions or financial strains.

Why It Matters

This filing signals a new material agreement and financial obligation for Harvard Apparatus Regenerative Technology, Inc., which could significantly alter its financial position and operational strategy.

Risk Assessment

Risk Level: medium — The filing indicates new financial obligations and material agreements without specific details, creating uncertainty about their potential positive or negative impact.

Analyst Insight

A smart investor would await further details on the 'Material Definitive Agreement' and 'Direct Financial Obligation' to assess their financial implications before making any investment decisions regarding Harvard Apparatus Regenerative Technology, Inc.

Key Players & Entities

• Harvard Apparatus Regenerative Technology, Inc. (company) — the registrant filing the 8-K
• Biostage, Inc. (company) — former name of the registrant
• February 1, 2024 (date) — date of the earliest event reported
• February 6, 2024 (date) — date the 8-K was filed

FAQ

Key Financial Figures

• $500,000 — loan the Company an aggregate amount of $500,000 as evidenced by a Bridge Note executed
• $5,000,000 — hat includes gross proceeds of at least $5,000,000 or b) February 1, 2025. The Bridge Note

Filing Documents

• form8-k.htm (8-K) — 40KB
• ex10-1.htm (EX-10.1) — 33KB
• 0001493152-24-005102.txt ( ) — 253KB
• hrgn-20240201.xsd (EX-101.SCH) — 3KB
• hrgn-20240201_lab.xml (EX-101.LAB) — 34KB
• hrgn-20240201_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 4KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2024 Harvard Apparatus Regenerative Technology, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35853 45-5210462 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 84 October Hill Road , Suite 11 , Holliston , MA 01746 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (774) 233-7300 Biostage, Inc. (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock HRGN OTCQB Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 1.01. Entry into a Material Definitive Agreement. On February 1, 2024, Harvard Apparatus Regenerative Technology, Inc. (the " Company ") entered into a loan arrangement with Junli He, the Chairman and Chief Executive Officer of the Company (the " Lender "), pursuant to which the Lender has agreed to loan the Company an aggregate amount of $500,000 as evidenced by a Bridge Note executed by the Company in favor of, and accepted by, the Lender (the " Bridge Note "). The Bridge Note accrues interest at an annual fixed rate of 8%, and the principal amount thereof will be due and payable in full, together with all accrued and unpaid interest thereon, on the earlier to occur of a) the closing date (or later date of capital being provided pertaining to such continued offering that the following threshold is tripped) of the Company's next capital raise that includes gross proceeds of at least $5,000,000 or b) February 1, 2025. The Bridge Note provides for optional conversion at the discretion of the Lender, contains covenants, and provides for certain events of default including if the Company fails to pay when due any amount owed thereunder, fails to comply with any agreement, covenant, condition, provision or term contained therein and other customary events of default. The foregoing description of the Bridge Note does not purport to be complete and is qualified in its entirety by reference to the full text of such document, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. Item 2.03. Creation of a Certain Direct Financial Obligation. The information set forth under Item 1.01 of this Report is incorporated herein by reference. Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Title 10.1 Bridge Note dated as of February 1, 2024, by Harvard Apparatus Regenerative Technology, Inc. in favor of Junli He. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC. Date: February 6, 2024 By: /s/ Joseph Damasio Joseph Damasio Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR